Neurology · 2026
Risk of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis After Initiation of Antiseizure Medication: A Danish Nationwide Cohort Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Heerfordt Ida M, Mogensen Mette, Horwitz Anna, Andersen Jon Trærup, Gotfredsen Ditte Resendal, Gade Christina, Heerfordt Christian Kjer, Olsen Rasmus Huan, Horwitz Henrik
Аннотация
BACKGROUND AND OBJECTIVES: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are serious cutaneous adverse reactions associated with several antiseizure medications, particularly lamotrigine and carbamazepine. We assessed the 90-day absolute risk of SJS/TEN after initiation of antiseizure medications in a nationwide Danish cohort and compared medication-specific risks with the general population background risk.
METHODS: All Danish residents initiating any of 25 antiseizure medications between 1995 and 2024 were included. Initiations and incident SJS/TEN diagnoses were identified through Danish registries. For each medication, we calculated the 90-day risk of SJS/TEN (cases per 100,000 initiators) with 95% CIs. Among cases, time from initiation to diagnosis was summarized using cumulative percentages, and 1-year mortality was assessed. General-population SJS/TEN cases were identified to estimate the 90-day background risk.
RESULTS: Among 1,388,397 antiseizure medication initiations, the median age was 55.3 years (interquartile range [IQR] 40.2-69.9), and 56% were in female individuals. Within 90 days after initiation, 83 SJS/TEN cases occurred, most within the first weeks. One-year mortality among cases was 17%. Overall, these 83 cases accounted for 7% of all incident SJS/TEN cases in Denmark during the study period. The highest observed absolute risk was for lamotrigine (29.31 per 100,000 initiators; 95% CI 21.46-39.09), followed by carbamazepine (16.66; 95% CI 8.32-29.80), phenobarbital (15.84; 95% CI 5.14-36.96), oxcarbazepine (11.25; 95% CI 3.65-26.25), and valproic acid (7.31; 95% CI 2.68-15.91). Risks were lower for gabapentinoids, including pregabalin (2.26; 95% CI 0.83-4.92) and gabapentin (1.24; 95% CI 0.50-2.56). No SJS/TEN cases were observed for several newer antiseizure medications, although limited exposure for some precludes firm conclusions. The estimated 90-day background risk in the general population was 0.17 per 100,000 individuals (95% CI 0.16-0.18).
DISCUSSION: This nationwide Danish study provides updated, population-based absolute risk estimates of SJS/TEN within 90 days of initiating 25 antiseizure medications in routine care and places these risks in the context of the general-population background risk. These estimates update and extend older evidence and provide a contemporary reference for SJS/TEN risk in antiseizure pharmacotherapy, including newer agents. The findings may also support risk communication around antiseizure medication initiation.
METHODS: All Danish residents initiating any of 25 antiseizure medications between 1995 and 2024 were included. Initiations and incident SJS/TEN diagnoses were identified through Danish registries. For each medication, we calculated the 90-day risk of SJS/TEN (cases per 100,000 initiators) with 95% CIs. Among cases, time from initiation to diagnosis was summarized using cumulative percentages, and 1-year mortality was assessed. General-population SJS/TEN cases were identified to estimate the 90-day background risk.
RESULTS: Among 1,388,397 antiseizure medication initiations, the median age was 55.3 years (interquartile range [IQR] 40.2-69.9), and 56% were in female individuals. Within 90 days after initiation, 83 SJS/TEN cases occurred, most within the first weeks. One-year mortality among cases was 17%. Overall, these 83 cases accounted for 7% of all incident SJS/TEN cases in Denmark during the study period. The highest observed absolute risk was for lamotrigine (29.31 per 100,000 initiators; 95% CI 21.46-39.09), followed by carbamazepine (16.66; 95% CI 8.32-29.80), phenobarbital (15.84; 95% CI 5.14-36.96), oxcarbazepine (11.25; 95% CI 3.65-26.25), and valproic acid (7.31; 95% CI 2.68-15.91). Risks were lower for gabapentinoids, including pregabalin (2.26; 95% CI 0.83-4.92) and gabapentin (1.24; 95% CI 0.50-2.56). No SJS/TEN cases were observed for several newer antiseizure medications, although limited exposure for some precludes firm conclusions. The estimated 90-day background risk in the general population was 0.17 per 100,000 individuals (95% CI 0.16-0.18).
DISCUSSION: This nationwide Danish study provides updated, population-based absolute risk estimates of SJS/TEN within 90 days of initiating 25 antiseizure medications in routine care and places these risks in the context of the general-population background risk. These estimates update and extend older evidence and provide a contemporary reference for SJS/TEN risk in antiseizure pharmacotherapy, including newer agents. The findings may also support risk communication around antiseizure medication initiation.